Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service vitreoretinal surgery cases in New York: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 5% on average (216 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 47 | 4,153 | 46% |
| 2020 | 32 | 3,328 | 48% |
| 2021 | 38 | 3,641 | 51% |
| 2022 | 45 | 3,611 | 53% |
| 2023 | 51 | 3,513 | 55% |
| 2024 | 42 | 3,504 | 57% |
| 2025 from claims | – | 3,564 3,271–3,771 | 58% |
| 2026 forecast | – | 3,596 3,164–4,150 | 58% |
| 2027 forecast | – | 3,613 3,088–4,305 | 59% |
| 2028 forecast | – | 3,629 3,028–4,443 | 59% |
| 2029 forecast | – | 3,644 2,977–4,570 | 60% |
| 2030 forecast | – | 3,659 2,932–4,689 | 60% |
Pars plana vitrectomy and retinal detachment repair. Professional codes (what the surgeon bills): CPT 67036, 67040, 67041, 67042, 67108, 67113.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 43% of the cases CMS names in New York; 26 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 52% hospital outpatient, 48% surgery center. The share outside the hospital has moved +15 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Pennsylvania | 45 | 3,182−0.1%/yr | −0.1%/yr | 2.4 | 49% | 3,020 in 2030−0.9%/yr |
| New Jersey | 23 | 1,908−1.3%/yr | −1.3%/yr | 1.8 | 56% | 1,990 in 2030+0.7%/yr |
| Massachusetts | 29 | 1,871−4.2%/yr | −4.2%/yr | 2.0 | 38% | 2,190 in 2030+2.6%/yr |
| Connecticut | 6 | 441−6.9%/yr | −6.9%/yr | 1.3 | 97% | 470 in 2030+1.1%/yr |
| Maine | 5 | 254−4%/yr | −4%/yr | 1.6 | 100% | 240 in 2030−1.2%/yr |
| New Hampshire | 3 | 201+0.6%/yr | +0.6%/yr | 0.9 | 89% | 290 in 2030+6.5%/yr |
| Rhode Island | 0 | 115−2.6%/yr | −2.6%/yr | 1.3 | 100% | 70 in 2030−8%/yr |
| Vermont | 2 | 101+27%/yr | +27%/yr | 0.9 | 0% | 180 in 2030+9.9%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Cataract & MIGS | 588 | 82,565−2.7%/yr | −2.7%/yr | 44.50.9× | 75% | 85,900 in 2030+0.7%/yr |
Vitreoretinal surgery in every state, and its device makers · Every procedure market in New York · Every state · Compare with Pennsylvania
Alcon leads with 71% of company spending on these surgeons in 2025, +11 pts on 2024.
In 2025, 16 companies reported engagement with New York’s surgeons worth $528K in consulting, speaking, meals and travel tied to these products, about $13K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 0 clearances and approvals in the category, 3 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.